Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
606 people get CORT articles and Market Currents by email alert.
Get email alerts on CORT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Marketwire (May 2, 2013)
-
Marketwire (Apr 26, 2013)
-
-
Marketwire (Mar 7, 2013)
-
-
Marketwire (Feb 12, 2013)
-
-
-
-
-
-
Marketwire (Oct 31, 2012)
-
Marketwire (Oct 15, 2012)
-
-
-
3 Liquid Biotech Stocks With Impressive Growth ProjectionsZetaKap • Sun, Aug 12, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Corcept Stock Continues To Rally On Weight Loss NewsH.S. Ayoub • Wed, Jun 27, 2007 -
Corcept's Crash Not Necessarily What it SeemsFredric Cohen, M.D. • Mon, Aug 28, 2006
-
-
-
-
-
-
-
3 Liquid Biotech Stocks With Impressive Growth ProjectionsZetaKap • Sun, Aug 12, 2012
-
-
-
Hedge Funds Are Buying These 10 High-Growth Biotech StocksKapitall • Sat, Jul 14, 2012 -
8 High Growth Small Caps With Analyst LoveZetaKap • Wed, Jun 20, 2012
-
-
-
-
7 Stocks Deeply Discounted From Target Price Seeing Short CoveringKapitall • Tue, Mar 27, 2012
-
-
-
-
-
-
Marketwire (May 2, 2013)
-
Marketwire (Apr 26, 2013)
-
Marketwire (Mar 7, 2013)
-
Marketwire (Feb 12, 2013)
-
Marketwire (Oct 31, 2012)
-
Marketwire (Oct 15, 2012)
-
Marketwire (Aug 7, 2012)
-
Marketwire (Jul 2, 2012)
-
Marketwire (Jul 2, 2012)
-
Marketwire (May 3, 2012)
-
Marketwire (Mar 26, 2012)
-
at MarketWatch.com (Feb 21, 2012)
CORT vs. ETF Alternatives
Company Description
Currently, there's no company description for CORT.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 3, 6:50 AM Corcept Therapeutics (CORT): Q1 EPS of -$0.10 misses by $0.01. Revenue of $1.72M misses by $0.76M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 7, 5:23 PM More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym. Comment! [Healthcare, Earnings]
- Thursday, March 7, 5:17 PM Corcept Therapeutics (CORT): Q4 EPS of -$0.09 in-line. Revenue of $1.4M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Scott Matusow
Trade and buy Alert, Bought $CORT at 2.00, target opinion per chart = $2.50 short term. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
anonymous#12
CORT, korlym sales seemed pretty weak taking in consideration it is a orphan drug indication. Neutral. - View all 0 replies
-
ZetaKap
3 Liquid Biotech Stocks With Impressive Growth Projections http://bit.ly/NrEmOe $ANIK $CBPO $CORT @ZetaKap - View all 0 replies
-
- View all 0 replies
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.